fda stops semaglutide compounding Novo asks to bar compounders from making copies FDA issues warning about some

Although numerous studies have compared the available GLP-1 receptor agonists, few have directly explored the effects of switching between these agents, highlighting a need for further research

Legal Status and Use in Research Tirzepatide is FDA approved for type 2 diabetes

Back Finan, B, Ma, T, Ottaway, M (20 Oct 2013) 'Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans', Science Translational Medicine , 5/209, 2-9a151

Siegel notes is not considered a side effect for semaglutide or tirzepatide

First: plan for long-term, possibly lifelong therapy

Additionally, health care providers should be vigilant when prescribing and administering compounded semaglutide, as there may be different concentrations available